{"DataElement":{"publicId":"2181412","version":"1","preferredName":"Myeloma Treatment Prior Regimen Type","preferredDefinition":"the description a treatment regimen given to a patient for the multiple myeloma prior to enrolling in a myeloma clinical protocol.","longName":"MYE_TX_PRI_RGM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2196067","version":"1","preferredName":"Myeloma Treatment Prior Regimen","preferredDefinition":"information related to the prior treatment regimen for myeloma.","longName":"MYE_TX_PRIOR_RGM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206928","version":"1","preferredName":"Myeloma Therapy","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C3242:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0FBD-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207592","version":"1","preferredName":"Prior Regimen","preferredDefinition":"Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C25629:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2971-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE34D0DE-0AA2-038E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181411","version":"1","preferredName":"Myeloma Treatment Prior Regimen Type","preferredDefinition":"information related to the type of prior treatment regimen administered to a patient with myeloma.","longName":"MYE_TX_PRI_RGM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Carmustine (BCNU)","valueDescription":"Carmustine (BCNU)","ValueMeaning":{"publicId":"2568520","version":"1","preferredName":"Carmustine (BCNU)","longName":"2568520v1.00","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B563-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Chlorambucil","valueDescription":"Chlorambucil","ValueMeaning":{"publicId":"2577804","version":"1","preferredName":"Chlorambucil","longName":"2577804","preferredDefinition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil","conceptCode":"C362","definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A458-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Chlorambucil/prednisone","valueDescription":"Chlorambucil/prednisone","ValueMeaning":{"publicId":"2568521","version":"1","preferredName":"Chlorambucil/prednisone","longName":"2568521v1.00","preferredDefinition":"A chemotherapy regimen consisting of chlorambucil and prednisone used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil/Prednisone Regimen","conceptCode":"C63752","definition":"A chemotherapy regimen consisting of chlorambucil and prednisone used for the treatment of chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A45C-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Colchicine","valueDescription":"Colchicine","ValueMeaning":{"publicId":"2577831","version":"1","preferredName":"Colchicine","longName":"2577831","preferredDefinition":"An alkaloid isolated from Colchicum autumnale L. and in other Colchicum species. Colchicine binds to tubulin, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colchicine","conceptCode":"C385","definition":"An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activities. The exact mechanism of action by which colchicines exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals.  Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A460-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroids","ValueMeaning":{"publicId":"2568522","version":"1","preferredName":"Corticosteroids","longName":"2568522v1.00","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A464-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CP","valueDescription":"CP","ValueMeaning":{"publicId":"2568523","version":"1","preferredName":"CP","longName":"2568523v1.00","preferredDefinition":"A chemotherapy regimen consisting of chlorambucil and prednisone used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil/Prednisone Regimen","conceptCode":"C63752","definition":"A chemotherapy regimen consisting of chlorambucil and prednisone used for the treatment of chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A468-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"C-VAMP","valueDescription":"C-VAMP","ValueMeaning":{"publicId":"2568524","version":"1","preferredName":"C-VAMP","longName":"2568524v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._A regimen containing vincristine, doxorubicin, methotrexate and prednisone used in combination with radiation therapy for the treatment of low-risk, childhood Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"VAMP Regimen","conceptCode":"C67161","definition":"A regimen containing vincristine, doxorubicin, methotrexate and prednisone used in combination with radiation therapy for the treatment of low-risk, childhood Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E625-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CVP","valueDescription":"CVP","ValueMeaning":{"publicId":"2568525","version":"1","preferredName":"CVP","longName":"2568525v1.00","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CVP Regimen","conceptCode":"C9573","definition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E629-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"CYCLOPHOSPHAMIDE","ValueMeaning":{"publicId":"2561009","version":"1","preferredName":"CYCLOPHOSPHAMIDE","longName":"2561009v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E62C-3CB0-E034-0003BA12F5E7","beginDate":"2002-04-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cyclophosphamide IV high dose (>=2400 mg/m2/month)","valueDescription":"Cyclophosphamide IV high dose (>=2400 mg/m2/month)","ValueMeaning":{"publicId":"2568526","version":"1","preferredName":"Cyclophosphamide IV high dose (>=2400 mg/m2/month)","longName":"2568526v1.00","preferredDefinition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein._An elevated level or position or degree; greater than normal in degree or intensity or amount._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E630-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cyclophosphamide IV low dose (<2400 mg/m2/month)","valueDescription":"Cyclophosphamide IV low dose (<2400 mg/m2/month)","ValueMeaning":{"publicId":"2568527","version":"1","preferredName":"Cyclophosphamide IV low dose (<2400 mg/m2/month)","longName":"2568527v1.00","preferredDefinition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein._A minimum level or position or degree; less than normal in degree, intensity or amount._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E634-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cyclophosphamide/prednisone","valueDescription":"Cyclophosphamide/prednisone","ValueMeaning":{"publicId":"2568528","version":"1","preferredName":"Cyclophosphamide/prednisone","longName":"2568528v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E638-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"DCEP","valueDescription":"DCEP","ValueMeaning":{"publicId":"2568529","version":"1","preferredName":"DCEP","longName":"2568529v1.00","preferredDefinition":"A chemotherapy regimen consisting of dexamethasone, cyclophosphamide, etoposide, and cisplatin that may be used as a salvage regimen for relapsed and/or refractory plasma cell myeloma and/or as a mobilization regimen, followed by granulocyte colony-stimulating factor (G-CSF), for peripheral blood stem cell (PBSC) collection in plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DCEP Regimen","conceptCode":"C137681","definition":"A chemotherapy regimen consisting of dexamethasone, cyclophosphamide, etoposide, and cisplatin that may be used as a salvage regimen for relapsed and/or refractory plasma cell myeloma and/or as a mobilization regimen, followed by granulocyte colony-stimulating factor (G-CSF), for peripheral blood stem cell (PBSC) collection in plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E63C-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"2568530","version":"1","preferredName":"Dexamethasone","longName":"2568530v1.00","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E640-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"D-PACE","valueDescription":"D-PACE","ValueMeaning":{"publicId":"2568531","version":"1","preferredName":"D-PACE","longName":"2568531v1.00","preferredDefinition":"A chemotherapy regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DPACE Regimen","conceptCode":"C137680","definition":"A chemotherapy regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E644-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"DT-PACE","valueDescription":"DT-PACE","ValueMeaning":{"publicId":"2568532","version":"1","preferredName":"DT-PACE","longName":"2568532v1.00","preferredDefinition":"A regimen consisting of dexamethasone, thalidomide (DT) and cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) used for the treatment of relapsed and refractory plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DT-PACE Regimen","conceptCode":"C63501","definition":"A regimen consisting of dexamethasone, thalidomide (DT) and cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) used for the treatment of relapsed and refractory plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1921-E648-3CB0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"EDAP/ECHEP","valueDescription":"EDAP/ECHEP","ValueMeaning":{"publicId":"2568533","version":"1","preferredName":"EDAP/ECHEP","longName":"2568533","preferredDefinition":"EDAP/ECHEP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F4AC-CE54-3CAA-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Etoposide (VP16)","valueDescription":"Etoposide (VP16)","ValueMeaning":{"publicId":"2568534","version":"1","preferredName":"Etoposide (VP16)","longName":"2568534v1.00","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F4AC-CE58-3CAA-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":"Fludarabine","ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F4AC-CE5C-3CAA-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fludara/CTX","valueDescription":"Fludara/CTX","ValueMeaning":{"publicId":"2568536","version":"1","preferredName":"Fludara/CTX","longName":"2568536v1.00","preferredDefinition":"A regimen consisting of fludarabine and cyclophosphamide used as initial treatment for chronic lymphocytic leukemia (CLL); also used for the treatment of relapsed or refractory mantle cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FC Regimen","conceptCode":"C63444","definition":"A regimen consisting of fludarabine and cyclophosphamide used as initial treatment for chronic lymphocytic leukemia (CLL); also used for the treatment of relapsed or refractory mantle cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F4AC-CE60-3CAA-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fludara/CTX/Rituxan (FCR)","valueDescription":"Fludara/CTX/Rituxan (FCR)","ValueMeaning":{"publicId":"2568537","version":"1","preferredName":"Fludara/CTX/Rituxan (FCR)","longName":"2568537v1.00","preferredDefinition":"A regimen consisting of fludarabine, cyclophosphamide and rituximab that can be used for the treatment of chronic lymphocytic leukemia (CLL) and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FCR Regimen","conceptCode":"C63755","definition":"A regimen consisting of fludarabine, cyclophosphamide and rituximab that can be used for the treatment of chronic lymphocytic leukemia (CLL) and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F4AC-CE64-3CAA-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fludara/Rituxan","valueDescription":"Fludara/Rituxan","ValueMeaning":{"publicId":"2568538","version":"1","preferredName":"Fludara/Rituxan","longName":"2568538v1.00","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A46C-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"High dose steroids (e.g., Dex, Solu-Medrol)","valueDescription":"High dose steroids (e.g., Dex, Solu-Medrol)","ValueMeaning":{"publicId":"2568539","version":"1","preferredName":"High dose steroids (e.g., Dex, Solu-Medrol)","longName":"2568539v1.00","preferredDefinition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells._The use of exogenous steroids for the treatment of any disease or disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Dose Chemotherapy","conceptCode":"C15807","definition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Steroid Therapy","conceptCode":"C15370","definition":"The use of exogenous steroids for the treatment of any disease or disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A470-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"HyperCVAD","valueDescription":"HyperCVAD","ValueMeaning":{"publicId":"2568540","version":"1","preferredName":"HyperCVAD","longName":"2568540v1.00","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A474-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"INTERFERON","ValueMeaning":{"publicId":"2558977","version":"1","preferredName":"INTERFERON","longName":"2558977v1.00","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B36E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A477-3CBD-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Interleukin-2","valueDescription":"Interleukin-2","ValueMeaning":{"publicId":"2578198","version":"1","preferredName":"Interleukin-2","longName":"2578198","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A47B-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Iododeoxyrubicin","valueDescription":"Iododeoxyrubicin","ValueMeaning":{"publicId":"2568541","version":"1","preferredName":"Iododeoxyrubicin","longName":"2568541v1.00","preferredDefinition":"An iodinated analogue of deoxyuridine, with antiviral activity against herpes simplex virus (HSV) and potential radiosensitizing activities. Upon ocular administration, idoxuridine (IUdR) is converted to its mono-, di-, and triphosphate forms, is incorporated into DNA and disrupts viral replication. Upon oral administration of the idoxuridine prodrug ropidoxuridine and hepatic conversion by aldehyde oxidase into idoxuridine, this agent incorporates into DNA and sensitizes cells to ionizing radiation by increasing DNA strand breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idoxuridine","conceptCode":"C563","definition":"An iodinated analogue of deoxyuridine, with antiviral activity against herpes simplex virus (HSV) and potential radiosensitizing activities. Upon ocular administration, idoxuridine (IUdR) is converted to its mono-, di-, and triphosphate forms, is incorporated into DNA and disrupts viral replication. Upon oral administration of the idoxuridine prodrug ropidoxuridine and hepatic conversion by aldehyde oxidase into idoxuridine, this agent incorporates into DNA and sensitizes cells to ionizing radiation by increasing DNA strand breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B567-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Melphalan (LPAM)","valueDescription":"Melphalan (LPAM)","ValueMeaning":{"publicId":"2568542","version":"1","preferredName":"Melphalan (LPAM)","longName":"2568542v1.00","preferredDefinition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B56B-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Melphalan IV high dose (other than transplant, e.g., >=25 mg/m2/month)","valueDescription":"Melphalan IV high dose (other than transplant, e.g., >=25 mg/m2/month)","ValueMeaning":{"publicId":"2568543","version":"1","preferredName":"Melphalan IV high dose (other than transplant, e.g., >=25 mg/m2/month)","longName":"2568543v1.00","preferredDefinition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein._A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells._A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"High Dose Chemotherapy","conceptCode":"C15807","definition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B56F-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"MOCCA","valueDescription":"MOCCA","ValueMeaning":{"publicId":"2568544","version":"1","preferredName":"MOCCA","longName":"2568544v1.00","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)_A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)_A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells._A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B573-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"MP","valueDescription":"MP","ValueMeaning":{"publicId":"2568545","version":"1","preferredName":"MP","longName":"2568545v1.00","preferredDefinition":"A regimen consisting of melphalan and prednisone used as induction treatment for plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan/Prednisone Regimen","conceptCode":"C63497","definition":"A regimen consisting of melphalan and prednisone used as induction treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B577-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nitrosurea","valueDescription":"Nitrosurea","ValueMeaning":{"publicId":"2568546","version":"1","preferredName":"Nitrosurea","longName":"2568546v1.00","preferredDefinition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A47F-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418ED57-A483-3CBD-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"PS-341","valueDescription":"PS-341","ValueMeaning":{"publicId":"2568548","version":"1","preferredName":"PS-341","longName":"2568548v1.00","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9866-F40D-66E6-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CHOP","valueDescription":"CHOP","ValueMeaning":{"publicId":"2567435","version":"1","preferredName":"CHOP","longName":"2567435v1.00","preferredDefinition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D478-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9866-F410-66E6-E034-0003BA12F5E7","beginDate":"2003-12-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"R-CHOP","valueDescription":"R-CHOP","ValueMeaning":{"publicId":"2568549","version":"1","preferredName":"R-CHOP","longName":"2568549v1.00","preferredDefinition":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOP Regimen","conceptCode":"C9760","definition":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9866-F414-66E6-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Revimid","valueDescription":"Revimid","ValueMeaning":{"publicId":"2568550","version":"1","preferredName":"Revimid","longName":"2568550v1.00","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9866-F418-66E6-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Rituxan","valueDescription":"Rituxan","ValueMeaning":{"publicId":"2568551","version":"1","preferredName":"Rituxan","longName":"2568551v1.00","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9866-F41C-66E6-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thal-Dex","valueDescription":"Thal-Dex","ValueMeaning":{"publicId":"2568552","version":"1","preferredName":"Thal-Dex","longName":"2568552v1.00","preferredDefinition":"A regimen consisting of thalidomide and dexamethasone used for the treatment for plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TD Regimen","conceptCode":"C63499","definition":"A regimen consisting of thalidomide and dexamethasone used for the treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9FD9-ED30-671A-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Thalidomide","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"2568117","version":"1","preferredName":"Thalidomide","longName":"2568117","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D722-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-26","modifiedBy":"REEVESD","dateModified":"2016-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9FD9-ED34-671A-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Transplant","valueDescription":"Transplant","ValueMeaning":{"publicId":"2563821","version":"1","preferredName":"Transplant","longName":"2563821v1.00","preferredDefinition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C65A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9FD9-ED37-671A-E034-0003BA12F5E7","beginDate":"2002-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"VAD","valueDescription":"VAD","ValueMeaning":{"publicId":"2568553","version":"1","preferredName":"VAD","longName":"2568553v1.00","preferredDefinition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAD Regimen","conceptCode":"C63498","definition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9FD9-ED3B-671A-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"VAMP","valueDescription":"VAMP","ValueMeaning":{"publicId":"2568554","version":"1","preferredName":"VAMP","longName":"2568554v1.00","preferredDefinition":"A regimen containing vincristine, doxorubicin, methotrexate and prednisone used in combination with radiation therapy for the treatment of low-risk, childhood Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAMP Regimen","conceptCode":"C67161","definition":"A regimen containing vincristine, doxorubicin, methotrexate and prednisone used in combination with radiation therapy for the treatment of low-risk, childhood Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A9FD9-ED3F-671A-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"VBAP","valueDescription":"VBAP","ValueMeaning":{"publicId":"2568555","version":"1","preferredName":"VBAP","longName":"2568555v1.00","preferredDefinition":"A regimen consisting of carmustine, doxorubicin, prednisone and vincristine that can be used for the treatment of plasma cell (multiple) myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine/Doxorubicin/Prednisone/Vincristine Regimen","conceptCode":"C9653","definition":"A regimen consisting of carmustine, doxorubicin, prednisone and vincristine that can be used for the treatment of plasma cell (multiple) myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AA7E5-749E-66E0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"VBMCP (M-2)","valueDescription":"VBMCP (M-2)","ValueMeaning":{"publicId":"2568556","version":"1","preferredName":"VBMCP (M-2)","longName":"2568556v1.00","preferredDefinition":"A regimen consisting of vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone used for the treatment of plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VBMCP Regimen","conceptCode":"C64837","definition":"A regimen consisting of vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone used for the treatment of plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AA7E5-74A2-66E0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Vincristine (VCR)","valueDescription":"Vincristine (VCR)","ValueMeaning":{"publicId":"2568557","version":"1","preferredName":"Vincristine (VCR)","longName":"2568557v1.00","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8DA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AA7E5-74A6-66E0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"VMCP","valueDescription":"VMCP","ValueMeaning":{"publicId":"2568558","version":"1","preferredName":"VMCP","longName":"2568558v1.00","preferredDefinition":"A chemotherapy regimen consisting of vincristine, melphalan, cyclophosphamide, and prednisone that may be used in the treatment of plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VMCP Regimen","conceptCode":"C9661","definition":"A chemotherapy regimen consisting of vincristine, melphalan, cyclophosphamide, and prednisone that may be used in the treatment of plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AA7E5-74AA-66E0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Zevalin (Yttrium-90-anti-CD20)","valueDescription":"Zevalin (Yttrium-90-anti-CD20)","ValueMeaning":{"publicId":"2568559","version":"1","preferredName":"Zevalin (Yttrium-90-anti-CD20)","longName":"2568559v1.00","preferredDefinition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibritumomab Tiuxetan","conceptCode":"C29981","definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8DC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AA7E5-74AE-66E0-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AAAB8-5B99-66B3-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Arsenic compounds","valueDescription":"Arsenic compounds","ValueMeaning":{"publicId":"2568560","version":"1","preferredName":"Arsenic compounds","longName":"2568560v1.00","preferredDefinition":"A white, odorless, inorganic substance that contains the semi-metallic element arsenic usually in the 3 and 5-valence state, and emits toxic arsenic fumes when heated to decomposition. Arsenic compounds are primarily used in wood preservation. Exposure to this substance irritates skin and mucous membranes, and can affect the gastrointestinal tract, CNS, cardiovascular system, liver, kidneys and blood. Arsenic compounds are known human carcinogens and are associated with an increased risk of developing lung, skin, bladder, kidney, liver, prostate, digestive tract and colon cancer as well as cancer of the lymphatic and hematopoietic system. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic Compound","conceptCode":"C45557","definition":"A white, odorless, inorganic substance that contains the semi-metallic element arsenic usually in the 3 and 5-valence state, and emits toxic arsenic fumes when heated to decomposition. Arsenic compounds are primarily used in wood preservation. Exposure to this substance irritates skin and mucous membranes, and can affect the gastrointestinal tract, CNS, cardiovascular system, liver, kidneys and blood. Arsenic compounds are known human carcinogens and are associated with an increased risk of developing lung, skin, bladder, kidney, liver, prostate, digestive tract and colon cancer as well as cancer of the lymphatic and hematopoietic system. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8DD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41AAAB8-5B9C-66B3-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2-CDA/Rituxan","valueDescription":"2-CDA/Rituxan","ValueMeaning":{"publicId":"2568601","version":"1","preferredName":"2-CDA/Rituxan","longName":"2568601v1.00","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D906-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D4E434E9-7D9C-3036-E034-0003BA12F5E7","beginDate":"2004-03-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"ABCM","valueDescription":"ABCM","ValueMeaning":{"publicId":"2568766","version":"1","preferredName":"ABCM","longName":"2568766v1.00","preferredDefinition":"A chemotherapy regimen consisting of bleomycin, cyclophosphamide, doxorubicin and mitomycin used for the treatment of advanced ovarian carcinoma that is refractory to cisplatin therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin/Cyclophosphamide/Doxorubicin/Mitomycin Regimen","conceptCode":"C9907","definition":"A chemotherapy regimen consisting of bleomycin, cyclophosphamide, doxorubicin and mitomycin used for the treatment of advanced ovarian carcinoma that is refractory to cisplatin therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9AB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-22","endDate":null,"createdBy":"PWEST","dateCreated":"2004-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D63BAAC4-04A2-624A-E034-0003BA12F5E7","beginDate":"2004-03-22","endDate":null,"createdBy":"PWEST","dateCreated":"2004-03-22","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Melphalan (LPAM, single agent)","valueDescription":"Melphalan (LPAM)","ValueMeaning":{"publicId":"2568542","version":"1","preferredName":"Melphalan (LPAM)","longName":"2568542v1.00","preferredDefinition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D63BAAC4-04A6-624A-E034-0003BA12F5E7","beginDate":"2004-03-22","endDate":null,"createdBy":"PWEST","dateCreated":"2004-03-22","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2-chloro-deoxy-adenosine (2-CDA)","valueDescription":"2-chloro-deoxy-adenosine (2-CDA)","ValueMeaning":{"publicId":"2568512","version":"1","preferredName":"2-chloro-deoxy-adenosine (2-CDA)","longName":"2568512v1.00","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8AD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1D37-21E6-3CF4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2-CDA/RituxanABCM","valueDescription":"2-CDA/RituxanABCM","ValueMeaning":{"publicId":"2568513","version":"1","preferredName":"2-CDA/RituxanABCM","longName":"2568513v1.00","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)_A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)_A chemotherapy regimen consisting of bleomycin, cyclophosphamide, doxorubicin and mitomycin used for the treatment of advanced ovarian carcinoma that is refractory to cisplatin therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bleomycin/Cyclophosphamide/Doxorubicin/Mitomycin Regimen","conceptCode":"C9907","definition":"A chemotherapy regimen consisting of bleomycin, cyclophosphamide, doxorubicin and mitomycin used for the treatment of advanced ovarian carcinoma that is refractory to cisplatin therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1D37-21EA-3CF4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adriamycin","valueDescription":"ADRIAMYCIN","ValueMeaning":{"publicId":"2561704","version":"1","preferredName":"ADRIAMYCIN","longName":"2561704v1.00","preferredDefinition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin Hydrochloride","conceptCode":"C1326","definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1D37-21ED-3CF4-E034-0003BA12F5E7","beginDate":"2002-07-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Alpha-interferon","valueDescription":"Alpha-interferon","ValueMeaning":{"publicId":"2568514","version":"1","preferredName":"Alpha-interferon","longName":"2568514v1.00","preferredDefinition":"A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Interferon Alfa","conceptCode":"C225","definition":"A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8AF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1D37-21F1-3CF4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Anti-CD20 antibody","valueDescription":"Anti-CD20 antibody","ValueMeaning":{"publicId":"2568515","version":"1","preferredName":"Anti-CD20 antibody","longName":"2568515v1.00","preferredDefinition":"Any antibody that recognizes B-lymphocyte antigen CD20 protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD20 Antibody","conceptCode":"C118798","definition":"Any antibody that recognizes B-lymphocyte antigen CD20 protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D41A1D37-21F5-3CF4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Bexxar ([131]-I-anti-CD20)","valueDescription":"Bexxar ([131]-I-anti-CD20)","ValueMeaning":{"publicId":"2568516","version":"1","preferredName":"Bexxar ([131]-I-anti-CD20)","longName":"2568516v1.00","preferredDefinition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I 131 Tositumomab","conceptCode":"C2444","definition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B553-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Bisphosphonates (e.g., pamidronate or zoledronic acid)","valueDescription":"Bisphosphonates (e.g., pamidronate or zoledronic acid)","ValueMeaning":{"publicId":"2568517","version":"1","preferredName":"Bisphosphonates (e.g., pamidronate or zoledronic acid)","longName":"2568517v1.00","preferredDefinition":"A drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biphosphonate","conceptCode":"C443","definition":"A drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B557-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"BLT-D","valueDescription":"BLT-D","ValueMeaning":{"publicId":"2568518","version":"1","preferredName":"BLT-D","longName":"2568518v1.00","preferredDefinition":"A chemotherapy regimen consisting of clarithromycin, dexamethasone, and low-dose thalidomide for the treatment of plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BLT-D Regimen","conceptCode":"C161936","definition":"A chemotherapy regimen consisting of clarithromycin, dexamethasone, and low-dose thalidomide for the treatment of plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B55B-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"CAD","valueDescription":"CAD","ValueMeaning":{"publicId":"2568519","version":"1","preferredName":"CAD","longName":"2568519v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Doxorubicin Hydrochloride","conceptCode":"C1326","definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D418F685-B55F-3CB4-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Liposomal Doxorubicin","valueDescription":"Liposome-Encapsulated Doxorubicin Citrate","ValueMeaning":{"publicId":"2662264","version":"1","preferredName":"Liposome-Encapsulated Doxorubicin Citrate","longName":"2662264","preferredDefinition":"A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposome-Encapsulated Doxorubicin Citrate","conceptCode":"C61317","definition":"A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"34857986-EADB-1CED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34857986-EAF3-1CED-E044-0003BA3F9857","beginDate":"2007-07-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-05","modifiedBy":"CAMPBELB","dateModified":"2007-07-05","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"CC 5013 (Lenalidomide)","ValueMeaning":{"publicId":"2662266","version":"1","preferredName":"CC 5013 (Lenalidomide)","longName":"2662266","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"34857986-EB02-1CED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34857986-EB1A-1CED-E044-0003BA3F9857","beginDate":"2007-07-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-05","modifiedBy":"CAMPBELB","dateModified":"2007-07-05","deletedIndicator":"No"},{"value":"Vincristine, doxorubicin and dexamethasone","valueDescription":"Vincristine, doxorubicin and dexamethasone","ValueMeaning":{"publicId":"2647752","version":"1","preferredName":"Vincristine, doxorubicin and dexamethasone","longName":"2647752v1.00","preferredDefinition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAD Regimen","conceptCode":"C63498","definition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3242DCAA-6ECB-0EEC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3242E1DB-1B31-1930-E044-0003BA3F9857","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","deletedIndicator":"No"},{"value":"Thalidomide and dexamethasone","valueDescription":"Thalidomide and dexamethasone","ValueMeaning":{"publicId":"2647751","version":"1","preferredName":"Thalidomide and dexamethasone","longName":"2647751v1.00","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3242DB5A-0ADC-0945-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3242E1DB-1B43-1930-E044-0003BA3F9857","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","deletedIndicator":"No"},{"value":"Lenalidomide and dexamethasone","valueDescription":"Lenalidomide and dexamethasone","ValueMeaning":{"publicId":"2647750","version":"1","preferredName":"Lenalidomide and dexamethasone","longName":"2647750v1.00","preferredDefinition":"A regimen consisting of lenalidomide and dexamethasone that can be used in the treatment of plasma cell myeloma and systemic light chain amyloidosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone/Lenalidomide Regimen","conceptCode":"C64732","definition":"A regimen consisting of lenalidomide and dexamethasone that can be used in the treatment of plasma cell myeloma and systemic light chain amyloidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3242DA43-5F9C-17FB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3242E1DB-1B55-1930-E044-0003BA3F9857","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","deletedIndicator":"No"},{"value":"Liposomal doxorubicin and dexamethasone","valueDescription":"Liposomal doxorubicin and dexamethasone","ValueMeaning":{"publicId":"2647749","version":"1","preferredName":"Liposomal doxorubicin and dexamethasone","longName":"2647749v1.00","preferredDefinition":"A regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and Kaposi sarcomas; mycosis fungoides and Sezary syndrome; Castleman disease; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Doxorubicin Regimen","conceptCode":"C160080","definition":"A regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and Kaposi sarcomas; mycosis fungoides and Sezary syndrome; Castleman disease; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3242D8F2-A1C8-17EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3242E1DB-1B67-1930-E044-0003BA3F9857","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","deletedIndicator":"No"},{"value":"Cyclophosphamide, lenalidomide and dexamethasone","valueDescription":"Cyclophosphamide, lenalidomide and dexamethasone","ValueMeaning":{"publicId":"2647748","version":"1","preferredName":"Cyclophosphamide, lenalidomide and dexamethasone","longName":"2647748v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death._A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3242D73F-B3FA-0C19-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3242E1DB-1B79-1930-E044-0003BA3F9857","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"2738485","version":"1","preferredName":"Bortezomib","longName":"2738485","preferredDefinition":"A modified dipeptidyl boronic acid with antineoplastic activity. Via boronic acid moiety, bortezomib reversibly binds to the 26S proteasome, where degradation of ubiquinated proteins occurs. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis.  Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F951-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B4F74B9-A053-9960-E040-BB89AD4316C8","beginDate":"2009-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-01","modifiedBy":"ONEDATA","dateModified":"2009-06-01","deletedIndicator":"No"},{"value":"PD1/PDL1 inhibitor","valueDescription":"PD1/PDL1 inhibitor","ValueMeaning":{"publicId":"4573831","version":"1","preferredName":"PD1/PDL1 inhibitor","longName":"4573831v1.00","preferredDefinition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system._An agent designed to interfere with the activity of programmed death ligand 1 (PD-L1; CD274), a ligand for the receptor programmed cell death protein 1 (PD-1; PD1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PD1 Inhibitor","conceptCode":"C124946","definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"PD-L1 Inhibitor","conceptCode":"C191689","definition":"An agent designed to interfere with the activity of programmed death ligand 1 (PD-L1; CD274), a ligand for the receptor programmed cell death protein 1 (PD-1; PD1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DCC7-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DCE0-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DCEA-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Dacarbazine","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DCFF-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Dabrafenib","valueDescription":"Dabrafenib","ValueMeaning":{"publicId":"4539014","version":"1","preferredName":"Dabrafenib","longName":"4539014","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059E8F71-D4FF-7062-E050-BB89AD435032","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DD0A-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Vemurafenib","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DD15-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Adjuvant Pegylated Interferon - alfa","valueDescription":"Adjuvant Pegylated Interferon - alfa","ValueMeaning":{"publicId":"4573832","version":"1","preferredName":"Adjuvant Pegylated Interferon - alfa","longName":"4573832v1.00","preferredDefinition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself._A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pegylated Interferon Alfa","conceptCode":"C2491","definition":"A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DD20-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DD39-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Adjuvant Interferon - alfa","valueDescription":"Adjuvant Interferon - alfa","ValueMeaning":{"publicId":"4573833","version":"1","preferredName":"Adjuvant Interferon - alfa","longName":"4573833v1.00","preferredDefinition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself._A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interferon Alfa-N1","conceptCode":"C2220","definition":"A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071FB1D4-DD43-3C96-E050-BB89AD435506","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"071FB1D4-DD5C-3C96-E050-BB89AD435506","beginDate":"2014-11-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-05","modifiedBy":"ONEDATA","dateModified":"2014-11-05","deletedIndicator":"No"},{"value":"Other immunotherapy","valueDescription":"Immunotherapy Other","ValueMeaning":{"publicId":"4773271","version":"1","preferredName":"Immunotherapy Other","longName":"4773271","preferredDefinition":"Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"130FA8B6-F3C1-23FE-E050-BB89AD431F29","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"130FA8B6-F3DA-23FE-E050-BB89AD431F29","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"Other chemotherapy","valueDescription":"Chemotherapy other","ValueMeaning":{"publicId":"2572193","version":"1","preferredName":"Chemotherapy other","longName":"2572193v1.00","preferredDefinition":"A chemotherapy other than the one specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other Chemotherapy","conceptCode":"C174557","definition":"A chemotherapy other than the one specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E70E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-04","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"130FA8B6-F3EE-23FE-E050-BB89AD431F29","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"CTLA4 inhibitor","valueDescription":"CTLA4 inhibitor","ValueMeaning":{"publicId":"4773272","version":"1","preferredName":"CTLA4 inhibitor","longName":"4773272v1.00","preferredDefinition":"Any agent that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; CTLA4; CD152).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CTLA-4-targeting Agent","conceptCode":"C191738","definition":"Any agent that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; CTLA4; CD152).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"130FA8B6-F3F9-23FE-E050-BB89AD431F29","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"130FA8B6-F412-23FE-E050-BB89AD431F29","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"MEK inhibitor","valueDescription":"MEK inhibitor","ValueMeaning":{"publicId":"4773273","version":"1","preferredName":"MEK inhibitor","longName":"4773273v1.00","preferredDefinition":"Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen-activated protein kinase. Inhibition of mitogen-activated protein kinase kinase results in the inhibition of cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitogen-Activated Protein Kinase Kinase Inhibitor","conceptCode":"C69145","definition":"Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen-activated protein kinase. Inhibition of mitogen-activated protein kinase kinase results in the inhibition of cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"130FA8B6-F41C-23FE-E050-BB89AD431F29","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"130FA8B6-F435-23FE-E050-BB89AD431F29","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"BRAF inhibitor","valueDescription":"BRAF inhibitor","ValueMeaning":{"publicId":"4773274","version":"1","preferredName":"BRAF inhibitor","longName":"4773274v1.00","preferredDefinition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF Inhibitor","conceptCode":"C155322","definition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"130FA8B6-F43F-23FE-E050-BB89AD431F29","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"130FA8B6-F458-23FE-E050-BB89AD431F29","beginDate":"2015-04-06","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"Doxil/Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F0EDB3-9C70-C409-E050-BB89AD43048A","beginDate":"2015-03-10","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-03-10","modifiedBy":"ONEDATA","dateModified":"2015-03-10","deletedIndicator":"No"},{"value":"Bendamustine","valueDescription":"Bendamustine","ValueMeaning":{"publicId":"4862971","version":"1","preferredName":"Bendamustine","longName":"4862971","preferredDefinition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine","conceptCode":"C73261","definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1842453B-10A4-C393-E050-BB89AD436354","latestVersionIndicator":"Yes","beginDate":"2015-06-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-06-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1842453B-10BD-C393-E050-BB89AD436354","beginDate":"2015-06-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-06-11","modifiedBy":"ONEDATA","dateModified":"2015-06-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D41A2B21-B9D2-3CA8-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":"2023.9.24 Updated PV missing concepts. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811906","version":"1","longName":"Waldenstrom Macrogl","context":"CTEP"},{"publicId":"2811905","version":"1","longName":"Primary Amyloidosis","context":"CTEP"},{"publicId":"2811904","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"1-COMMENT","type":"COMMENT","description":"Instruction on template form: *Prior Treatment Regimen Name:","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Preferred Question Text","description":"Prior Treatment Regimen Name(s)","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Prior Treatment Regimen","url":null,"context":"NHLBI"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Prior Therapy","url":null,"context":"ECOG-ACRIN"},{"name":"ECOG CRF Text 2","type":"Alternate Question Text","description":"Prior agent","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D41A2B21-B9D6-3CA8-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ROUILLAS","dateModified":"2015-06-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}